Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Shuttle Pharmaceuticals Holdings, Inc.SHPH · Entity 8505 | Director | December 31, 2024 | February 07, 2025 |
| ZEVRA THERAPEUTICS, INC.ZVRA · Entity 5212 | CCO | February 03, 2026 | February 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Shuttle Pharmaceuticals Holdings, Inc.
Report date December 31, 2024 · Filed February 07, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 210,004 |
Reported balance
After 2024-12-23 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2024-12-23 · Grant · Acquired 209,790 · Balance 210,004 F1: Represents 209,790 restricted stock units ("RSUs") issued to the Reporting Person under the Shuttle Pharmaceuticals Holdings, Inc. 2018 Equity Incentive Plan. The 209,790 RSUs which are scheduled to vest in one third increments on each of 12/31/2025, 12/31/2026 and 12/31/2027. F2: Consists of (1) 214 shares of common stock and (2) 209,790 RSUs which remain subject to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 209,790 restricted stock units ("RSUs") issued to the Reporting Person under the Shuttle Pharmaceuticals Holdings, Inc. 2018 Equity Incentive Plan. The 209,790 RSUs which are scheduled to vest in one third increments on each of 12/31/2025, 12/31/2026 and 12/31/2027.
F2: Consists of (1) 214 shares of common stock and (2) 209,790 RSUs which remain subject to vesting.
ZEVRA THERAPEUTICS, INC.
Report date February 03, 2026 · Filed February 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,278 |
Reported balance
After 2026-02-03 transaction · row 1
1 source rowRow 1 · 2026-02-03 · Sale · Disposed 10,500 · Balance 62,278 F1: Adoption date of referenced 10b5-1(c) plan is: 3/27/2025. F2: This transaction was executed in multiple trades at prices ranging from $8.92 to $9.55. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: Adoption date of referenced 10b5-1(c) plan is: 3/27/2025.
F2: This transaction was executed in multiple trades at prices ranging from $8.92 to $9.55. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2026 Filed Feb 4, 2026 21:27 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | SaleCommon Stock | 10,500 | $9.19 | $96,500.25 |
DisclosureSEC source: 0001945557-26-000004 · wk-form4_1770240428.xml · nonDerivative · entry 1 Schafer Joshua · CIK 0001945557 · CCO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,278 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 3/27/2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $8.92 to $9.55. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 22:19 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionRestricted Stock Unit · Derivative | 35,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001945557-26-000002 · wk-form4_1770070744.xml · derivative · entry 7 Schafer Joshua · CIK 0001945557 · CCO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,333 Underlying: Common Stock · 35,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: One third of the restricted stock units vested and settled on each of January 31, 2025 and January 31, 2026. The remaining one third of the shares will vest and settle on January 31, 2027, subject to the Reporting person's continued service through such vesting date. F7 · derivative.expiration_date: One third of the restricted stock units vested and settled on each of January 31, 2025 and January 31, 2026. The remaining one third of the shares will vest and settle on January 31, 2027, subject to the Reporting person's continued service through such vesting date. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 22:19 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionCommon Stock | 35,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001945557-26-000002 · wk-form4_1770070744.xml · nonDerivative · entry 3 Schafer Joshua · CIK 0001945557 · CCO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,778 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 22:19 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionRestricted Stock Unit · Derivative | 11,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001945557-26-000002 · wk-form4_1770070744.xml · derivative · entry 6 Schafer Joshua · CIK 0001945557 · CCO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,667 Underlying: Common Stock · 11,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the shares will vest and settle in equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date. F6 · derivative.expiration_date: One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the shares will vest and settle in equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 22:19 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | SaleCommon Stock | 3,375 | $8.83 | $29,800.24 |
DisclosureSEC source: 0001945557-26-000002 · wk-form4_1770070744.xml · nonDerivative · entry 2 Schafer Joshua · CIK 0001945557 · CCO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,444 F2 · kind: Adoption date of referenced 10b5-1(c) plan is: 3/27/2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $8.64 to $9.03. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 22:19 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionCommon Stock | 11,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001945557-26-000002 · wk-form4_1770070744.xml · nonDerivative · entry 1 Schafer Joshua · CIK 0001945557 · CCO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 22:19 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $8.86 | $0.00 |
DisclosureSEC source: 0001945557-26-000002 · wk-form4_1770070744.xml · derivative · entry 5 Schafer Joshua · CIK 0001945557 · CCO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-01-28 F5 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 22:19 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantRestricted Stock Unit · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001945557-26-000002 · wk-form4_1770070744.xml · derivative · entry 4 Schafer Joshua · CIK 0001945557 · CCO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date. F4 · derivative.expiration_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 22:55 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | SaleCommon Stock | 10,500 | $7.86 | $82,526.85 |
DisclosureSEC source: 0001437749-25-004069 · rdgdoc.xml · nonDerivative · entry 1 Schafer Joshua · CIK 0001945557 · CCO & EVP, Bus. Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,486 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 10/15/2024 Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 22:22 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionRestricted Stock Unit · Derivative | 35,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-002627 · rdgdoc.xml · derivative · entry 2 Schafer Joshua · CIK 0001945557 · CCO & EVP, Bus. Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,667 Underlying: Common Stock · 35,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The first tranche of the restricted stock units vested and settled on January 31, 2025, and the remaining two tranches of the restricted stock units will vest and settle inequal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date. F2 · derivative.expiration_date: The first tranche of the restricted stock units vested and settled on January 31, 2025, and the remaining two tranches of the restricted stock units will vest and settle inequal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 22:22 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionCommon Stock | 35,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-002627 · rdgdoc.xml · nonDerivative · entry 1 Schafer Joshua · CIK 0001945557 · CCO & EVP, Bus. Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,986 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 30, 2025 Filed Feb 3, 2025 22:22 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantRestricted Stock Unit · Derivative | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-002627 · rdgdoc.xml · derivative · entry 4 Schafer Joshua · CIK 0001945557 · CCO & EVP, Bus. Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 30, 2026, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's continued service through such vesting date. F4 · derivative.expiration_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 30, 2026, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's continued service through such vesting date. Read SEC document |
| January 30, 2025 Filed Feb 3, 2025 22:22 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 68,000 | $0.00 Strike: $8.02 | $0.00 |
DisclosureSEC source: 0001437749-25-002627 · rdgdoc.xml · derivative · entry 3 Schafer Joshua · CIK 0001945557 · CCO & EVP, Bus. Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 68,000 shares Expires 2035-01-29 F3 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| December 31, 2024 Filed Feb 4, 2025 00:30 UTC | Shuttle Pharmaceuticals Holdings, Inc. SHPH · Entity 8505 | GrantCommon Stock | 209,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-004733 · ownership.xml · nonDerivative · entry 1 Schafer Joshua · CIK 0001945557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,004 F1 · shares: Represents 209,790 restricted stock units ("RSUs") issued to the Reporting Person under the Shuttle Pharmaceuticals Holdings, Inc. 2018 Equity Incentive Plan. The 209,790 RSUs which are scheduled to vest in one third increments on each of 12/31/2025, 12/31/2026 and 12/31/2027. F2 · balance_after: Consists of (1) 214 shares of common stock and (2) 209,790 RSUs which remain subject to vesting. Read SEC document |
| December 23, 2024 Filed Feb 7, 2025 00:34 UTC Amendment | Shuttle Pharmaceuticals Holdings, Inc. SHPH · Entity 8505 | GrantCommon Stock | 209,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-005267 · ownership.xml · nonDerivative · entry 1 Schafer Joshua · CIK 0001945557 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,004 F1 · shares: Represents 209,790 restricted stock units ("RSUs") issued to the Reporting Person under the Shuttle Pharmaceuticals Holdings, Inc. 2018 Equity Incentive Plan. The 209,790 RSUs which are scheduled to vest in one third increments on each of 12/31/2025, 12/31/2026 and 12/31/2027. F2 · balance_after: Consists of (1) 214 shares of common stock and (2) 209,790 RSUs which remain subject to vesting. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 02:22 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantRestricted Stock Unit · Derivative | 106,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-003036 · rdgdoc.xml · derivative · entry 1 Schafer Joshua · CIK 0001945557 · CCO & EVP, Bus. Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,000 Underlying: Common Stock · 106,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Grant to the Reporting Person of restricted stock units ("RSU"). F2 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 31, 2025, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's ongoing employment. F2 · derivative.expiration_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 31, 2025, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's ongoing employment. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 21:11 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 500 | $5.13 | $2,564.50 |
DisclosureSEC source: 0001437749-23-025318 · rdgdoc.xml · nonDerivative · entry 1 Schafer Joshua · CIK 0001945557 · CCO & EVP, Bus. Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,500 Read SEC document |
| May 19, 2023 Filed Jun 30, 2023 20:14 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 1,000 | $5.42 | $5,415.70 |
DisclosureSEC source: 0001437749-23-019035 · rdgdoc.xml · nonDerivative · entry 1 Schafer Joshua · CIK 0001945557 · CCO & EVP, Bus. Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 00:14 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 2,000 | $4.61 | $9,217.80 |
DisclosureSEC source: 0001437749-23-006771 · rdgdoc.xml · nonDerivative · entry 1 Schafer Joshua · CIK 0001945557 · CCO & EVP, Bus. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| January 09, 2023 Filed Jan 12, 2023 02:49 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $4.54 | $0.00 |
DisclosureSEC source: 0001437749-23-000915 · rdgdoc.xml · derivative · entry 1 Schafer Joshua · CIK 0001945557 · CCO & EVP, Bus. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2033-01-08 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2023 Employment Inducement Award Plan (the "Plan"). 25% of the shares will vest on January 6, 2024 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.